Self-harm Mental and Behavioural Disorders Self-harm
Conditions
Interventions
The study will test whether adding BlueIce to the usual care provided by specialist child and adolescent mental health services (CAMHS) for young people who self-harm reduces self-harm, improves how t
Sponsors
Oxford Health NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 12-17 years 2. Attending specialist CAMHS 3. History of self-harm (i.e. 2 or more episodes of self-harm over the past 12 months)
Exclusion criteria
Exclusion criteria: 1. Suicidal 2. Diagnosed with psychosis 3. Current safeguarding concerns (i.e. the young person has suffered abuse within the last 6 months or is the subject of a safeguarding investigation), 4. Significant developmental disorder (e.g. autism) which interferes with their ability to use the app 5. Insufficient understanding of English in order to use BlueIce. At present, BlueIce is only available in English.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Self-reported self-harm assessed by the self-harm inventory of the RTSHIA at baseline, 12 weeks and six months | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 15/06/2023: 1. Anxiety, measured by the Revised Child Anxiety and Depressions Scale (RCADS) at baseline, post-intervention (12 weeks) and follow-up (6 months) 2. Depression, assessed by the Mood and Feelings Questionnaire (MFQ) at baseline, post-intervention (12 weeks) and follow-up (6 months) 3. Hopelessness, assessed by The Beck Hopelessness Scale at baseline, post-intervention (12 weeks) and follow-up (6 months) 4. General behaviour, assessed by the Strengths and Difficulties Questionnaire (SDQ) at baseline, post-intervention (12 weeks) and follow-up (6 months) 5. Insomnia assessed by the Sleep Condition Indicator (SCI) at baseline, post intervention (12 weeks) and 6 months. 6 Health-related quality of life (HRQoL), assessed by the Child Health Utility 9D (CHUD 9D) at baseline, post-intervention (12 weeks) and follow-up (6 months) Previous secondary outcome measures: 1. Anxiety, measured by the Revised Child Anxiety and Depressions Scale (RCADS) at baseline, post-intervention (12 weeks) and follow-up (6 months) 2. Depression, assessed by the Mood and Feelings Questionnaire (MFQ) at baseline, post-intervention (12 weeks) and follow-up (6 months) 3. Hopelessness, assessed by The Beck Hopelessness Scale at baseline, post-intervention (12 weeks) and follow-up (6 months) 4. General behaviour, assessed by the Strengths and Difficulties Questionnaire (SDQ) at baseline, post-intervention (12 weeks) and follow-up (6 months) 5. Health-related quality of life (HRQoL), assessed by the Child Health Utility 9D (CHUD 9D) at baseline, post-intervention (12 weeks) and follow-up (6 months) | — |
Countries
England, United Kingdom
Outcome results
None listed